Compositions for treatment of systemic mastocytosis

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 45/06 (2006.01) A61K 31/506 (2006.01) A61K 31/553 (2006.01)

Patent

CA 2615598

The present invention relates to the use of the combination of tyrosine phosphate inhibitors AMN107 and PKC412 for the preparation of a drug for the treatment of a mast cell-related proliferative disease. The present invention is also drawn to a combination treatment of a tyrosine phosphate inhibitor and a TK-inhibitor that is effective against a mast cell-related proliferative disease, including especially systemic mastocytosis (SM) including aggressive SM (ASM) and mast cell leukemia (MCL).

La présente invention concerne l'utilisation de la combinaison d'inhibiteurs de tyrosine phosphate AMN107 et PKC412 pour la préparation d'un médicament destiné au traitement d'une maladie proliférative associée aux mastocytes. La présente invention concerne également une polythérapie associant un inhibiteur de tyrosine phosphate et un inhibiteur de TK qui est efficace contre une maladie proliférative associée aux mastocytes, notamment la mastocytose systémique (SM) comprenant la SM agressive (ASM) et la leucémie à mastocytes (MCL).

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Compositions for treatment of systemic mastocytosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions for treatment of systemic mastocytosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for treatment of systemic mastocytosis will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1523297

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.